Truist Upgrades Biogen to Buy Ahead of Alzheimer's Drug Data
Truist Securities upgraded Biogen (BIIB) from hold to buy with a raised price target, citing positive expectations for new data on its Alzheimer’s drug Diranersen and potential de-risking readouts. The firm anticipates the upcoming phase-two results could drive momentum in shares.
Tickers: $BIIB
Topics: Alzheimer's drug trials Biogen Investor sentiment Truist Securities upgrade